Clinical Trials Directory

Trials / Terminated

TerminatedNCT00464113

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
49 (actual)
Sponsor
Exelixis · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.

Conditions

Interventions

TypeNameDescription
DRUGXL2281-hour IV infusion

Timeline

Start date
2007-05-01
Primary completion
2010-12-01
Completion
2011-04-01
First posted
2007-04-20
Last updated
2015-08-21

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00464113. Inclusion in this directory is not an endorsement.